Charles Schwab Investment Management Inc Black Diamond Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 102,203 shares of BDTX stock, worth $325,005. This represents 0.0% of its overall portfolio holdings.
Number of Shares
102,203
Previous 14,484
605.63%
Holding current value
$325,005
Previous $73,000
552.05%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding BDTX
# of Institutions
101Shares Held
47.2MCall Options Held
108KPut Options Held
231K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$33.9 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$27.1 Million0.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$14.1 Million1.96% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$10.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.13MShares$6.78 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $116M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...